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The lysophospholipid sphingosine-1-phosphate (S1P) is a signaling molecule that acts through the binding to a 
family of 7-transmembrane G-protein–coupled receptors that 
include 5 high-affinity members (S1P1–5).1 S1P receptors mod-
ulate a variety of biological processes, including cell adhe-
sion, migration, and endocytosis with different and sometimes 
opposing effects on the regulation of cellular functions.2 In 
particular, endothelial S1P1 is involved in cytoskeletal rear-
rangement and formation of intercellular adherens junctions, 
its exposure to blood-borne S1P being required for the main-
tenance of blood–barrier integrity in defined vascular beds.3,4 
Also, genetic deletion demonstrates the nonredundant role of 
S1P1 in vascular maturation during embryogenesis, leading to 
embryonic lethality in knockout mice.5 Thus, chemical modu-
lators of S1P1 activity have been developed as putative thera-
peutic molecules acting to restore endothelial barrier integrity 
in various pathological conditions characterized by the dis-
ruption of endothelial cell–cell interaction in different organs, 
including lung, heart, kidney, and brain.4
Endothelial barrier integrity is dependent upon a complex 
network of molecular interactions involving adherens and 
tight junctions.6 S1P may affect endothelial cell–cell junctions 
by regulating assembly and expression of the major adherens 
junction component, vascular endothelial adhesion molecule 
VE-cadherin, and formation of zonula occludens 1 (ZO1)+ 
tight junctions.7–10 However, the molecular and functional 
bases of the impact of the S1P/S1P1 receptor system on endo-
thelial barrier integrity remain to be fully elucidated.
The teleost zebrafish (Danio rerio) represents a promising 
experimental model for in vivo analysis of the molecular and 
cellular mechanisms underlying blood vessel development and 
vascular dysfunctions.6 When compared with other vertebrate 
model systems, zebrafish offers many advantages, including 
ease of experimentation, drug administration, amenability to 
in vivo manipulation, and feasibility of reverse and forward 
genetic approaches.11 Also, zebrafish possesses a complex 
circulatory system similar to that of mammals and the optical 
transparency and ability to survive for several days without a 
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Objective—Endothelial sphingosine-1-phosphate (S1P) receptor-1 (S1P1) affects different vascular functions, including 
blood vessel maturation and permeability. Here, we characterized the role of the zS1P1 ortholog in vascular development 
in zebrafish.
Methods and Results—zS1P1 is expressed in dorsal aorta and posterior cardinal vein of zebrafish embryos at 24 to 
30 hours postfertilization. zS1P1 downregulation by antisense morpholino oligonucleotide injection causes early pericardial 
edema, lack of blood circulation, alterations of posterior cardinal vein structure, and late generalized edema. Also, 
zS1P1 morphants are characterized by downregulation of vascular endothelial cadherin (VE-cadherin) and Eph receptor 
EphB4a expression and by disorganization of zonula occludens 1 junctions in posterior cardinal vein endothelium, with 
no alterations of dorsal aorta endothelium. VE-cadherin knockdown results in similar vascular alterations, whereas VE-
cadherin overexpression is sufficient to rescue venous vascular integrity defects and EphB4a downregulation in zS1P1 
morphants. Finally, S1P1 small interfering RNA transfection and the S1P1 antagonist (R)-3-amino-(3-hexylphenylamino)-
4-oxobutylphosphonic acid (W146) cause EPHB4 receptor down-modulation in human umbilical vein endothelial cells 
and the assembly of zonula occludens 1 intercellular contacts is prevented by the EPHB4 antagonist TNYL-RAW peptide 
in these cells.
Conclusion—The data demonstrate a nonredundant role of zS1P1 in the regulation of venous endothelial barrier in zebrafish 
and identify a S1P1/VE-cadherin/EphB4a genetic pathway that controls venous vascular integrity. (Arterioscler Thromb 
Vasc Biol. 2012;32:e104-e116.)
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functioning circulation make the zebrafish embryo amenable 
for vascular biology studies.12
Expression of the zebrafish ortholog of the S1P1 receptor 
(zS1P1) has been observed in the zebrafish embryonic brain,13 
whereas zebrafish mutants of the S1P2 receptor ortholog miles 
apart (mil) show organogenesis defects of the heart,14 dem-
onstrating that bioactive lipid receptors play different roles 
in zebrafish development. In the present work, we performed 
the characterization and functional analysis of zS1P1 receptor 
during vascular development in zebrafish. zS1P1 is transiently 
expressed in the axial vasculature of the trunk of zebrafish 
embryos. zS1P1 knockdown caused defects of venous vas-
cular integrity, including VE-cadherin downregulation and 
disorganization of endothelial junctions, lack of blood circu-
lation, and late generalized edema. In association with these 
defects, zS1P1 morphants showed the downregulation of the 
Eph receptor EphB4a in venous axial endothelium. Similar 
defects were observed in VE-cadherin morphants and genetic 
evidence indicate that VE-cadherin is a zS1P1-regulated ele-
ment that controls venous endothelial barrier integrity by 
acting upstream of EphB4a. Finally, S1P1 small interfering 
RNA (siRNA) transfection and the specific S1P1 antagonist 
W14615 cause EPHB4 receptor downmodulation in human 
umbilical vein endothelial cells (HUVECs). Furthermore, a 
selective EPHB4 antagonist disrupts ZO1+ intercellular con-
tacts in these cells. Together, the results provide evidence for a 
nonredundant role for S1P1 in the regulation of blood–barrier 
integrity via a novel S1P1/VE-cadherin/EphB4a cascade that 
controls venous endothelial cell–cell junction assembly.
Materials and Methods
Reagents
S1P, dihydro-S1P (dhS1P), and W146 were from Avanti Polar Lipids 
Inc (Alabaster, AL). 5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-
3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole (SEW2871) was 
from Calbiochem (Nottingham, UK). Racemic 2-amino-2-[2-(4- 
octylphenyl)ethyl]-1,3-propanediol mono (dihydrogen phosphate) 
ester (FTY720-P) and [2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxa-
diazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino) ethanol (CYM-
5442) were synthesized as described.16,17 TNYL-RAW peptide 
(YNYLFSPNGPIARAW) and scrambled peptide SCR-WTL 
(WTLAIFARNYNGPSP)18,19 were kindly provided by Dr O. Salvucci 
(Bethesda, MD).
Zebrafish Stocks
Wild-type AB and transgenic tg(fli1:enhanced green fluores-
cent protein [EGFP])y120 zebrafish lines were maintained under 
standard conditions,21 and embryos were staged by hours post-
fertilization (hpf), as described.22 When specified, fertilized 
eggs were maintained in fish water containing 250 mmol/L 
D-mannitol (Sigma, St. Louis, MO) or treated with 0.66 mg/mL 
tricaine at different developmental stages and allowed to develop 
at 28.5°C.
Whole-Mount In Situ Hybridization
Digoxigenin-labeled RNA probes were transcribed from linear cDNA 
constructs (Roche Applied Science, Indianapolis, IN). Whole-mount 
in situ hybridization (ISH) was performed as described.23 For section-
ing, fixed embryos were dehydrated in ethanol series, cleared in xilol, 
and paraffin embedded overnight.
Morpholino-Mediated Knockdown of zS1P1  
and VE-cadherin
Antisense morpholino oligonucleotides (MO) (Gene Tools, Corvallis, 
OR) were directed against the 5ʹ untranslated region spanning the 
zS1P1 ATG start codon (zS1P1-MO: 5ʹ-AGTGTCTGGCGATTAGGT
CATCCAT-3ʹ) or were designed to complement exon–intron bound-
aries of the zebrafish VE-cadherin gene (VE-cadherin-MO: 5ʹ-TTT
ACAAGACCGTCTACCTTTCCAA-3ʹ). Standard MO (Std-MO: 
5ʹ-CCTCTTACCTCAGTTACAATTTATA-3ʹ) was used as con-
trol. Routinely, MOs were microinjected in 4.0 nL volume into 1- 
to 4-cell stage embryos at the concentration of 0.4 pmoles/embryo 
for zS1P1-MO or 1.0 pmoles/embryo for VE-cadherin-MO. A sub-
set of embryos was coinjected with 0.25 to 0.4 pmoles/embryo of 
zS1P1-MO and human S1P1 mRNA (70–100 pg/embryo), murine 
VE-cadherin mRNA (40–60 pg/embryo), or human VEGF-A mRNA 
(100 pg/embryo). zS1P1-MO shows no significant homology with 
human S1P1 mRNA and murine VE-cadherin mRNA sequences.
Microangiography
Tetramethylrhodamine isothiocyanate–dextran (molecular weight 
2.0×106; Invitrogen, Carlsbad, CA) was dissolved in double dis-
tilled water at 20 mg/mL and microinjected into the sinus venosus of 
zebrafish embryos at 50 hpf as described.24
Microscopy
Embryos were mounted in agarose-coated dishes and photographed 
under an epifluorescence Leica MZ16 F stereomicroscope (1× Plan 
Apo objective; NA, 0.141) equipped with a DFC480 digital cam-
era and ICM50 software version 2.8.1 (all from Leica, Wetzlar, 
Germany). Confocal images were acquired with an LSM 50 META 
confocal laser microscope (Carl Zeiss, Germany). When specified, 
dechorionated 28 hpf zebrafish embryos were fixed overnight at 4°C 
with 1.5% glutaraldehyde plus 4% paraformaldehyde in 0.1 mol/L 
sodium cacodylate buffer, pH 7.3. Then, embryos were postfixed for 
1 hour in sodium-cacodylate–buffered 1% osmium tetroxide, dehy-
drated in a graded ethanol series, transitioned to propylene oxide, and 
embedded in Epon 812-Araldite. Semithin sections (0.8 μm) were 
obtained using a Reichert UltracutE ultramicrotome, stained with 
gentian violet and basic fuchsin, observed under a Leica DM 6000B 
microscope and photographed with a digital camera.
ZO1 Immunofluorescence Analysis of 
Zebrafish Embryos
Control and MO-treated tg(fli1:EGFP)y1 embryos were fixed at 30 hpf 
in 4% paraformaldehyde for 2 hours at room temperature. Whole-
mount immunofluorescence analysis was performed as described25 
using a mouse anti-ZO1 antibody (Invitrogen) followed by Alexa 
Fluor 594 anti-mouse IgG (Invitrogen) and embryos were analysed 
by confocal laser microscopy.
zS1P1 Transfection in Mammalian Cells and  
cAMP Assay
The polymerase chain reaction (PCR) fragment with the full-
length coding sequence of zS1P1 was cloned from the total 
RNA isolated from zebrafish embryos at 24 hpf (primer 
set: forward, 5ʹ-TCCATGATGCAGTTTTTGGA-3ʹ; reverse, 
5ʹ-AGTTCCATCCCTCCAGTTT-3ʹ) into the pCRII-TOPO vector 
(Invitrogen). Next, the zS1P1 coding region was subcloned from 
pCRII-TOPO into the pcDNA5/FRT/TO vector (Invitrogen) 
using BamHI and XbaI (Fermentas Life Sciences, St. Leon-Rot, 
Germany). Chinese hamster ovary–FlpIn cells (Invitrogen) were 
maintained in Ham-F12 with L-glutamine, supplemented with 
100 U/mL penicillin, 100 μg/mL streptomycin, and 10% charcoal-
stripped fetal calf serum (Invitrogen). Ten μg of plasmid DNA 
were used for transfection into Chinese hamster ovary–FlpIn cells 
using Lipofectamine 2000 (Invitrogen). After 24 hours, transfected 
cells were washed with serum-free medium and serum starved for 
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16 hours. Next, transiently transfected cells were detached from 
the surface using cell dissociation buffer (Invitrogen), washed once 
with Hanks balanced salt solution, and resuspended in 5.0 mmol/L 
Hepes buffer, containing Hanks balanced salt solution with 0.05% 
fatty acid–free BSA (Sigma). Stimulation mixtures consisted of 
stimulation buffer with 3 μmol/L forskolin, 0.5 mmol/L 3-isobutyl-
1-methylxanthine (IBMX) (both from Sigma) and the concentration 
response curve of the indicated compounds. Cells (2500 per well) 
were added to the stimulation mixtures in a 1:1 ratio in a 384-well 
Optiplate (Perkin-Elmer, Zaventem, Belgium) and stimulated for 
30 minutes. The LANCE cAMP 384 kit (Perkin-Elmer) was used to 
determine the concentration of cAMP accumulated during stimulation 
according to the manufacturer’s protocol in a total volume of 20 μL. 
Measurements were performed 3 hours after adding detection buffer 
and antibody mixture using a Wallac 1420 Victor2 (PerkinElmer). 
Data are expressed as the potency of the indicated compound to 
inhibit forskolin–induced cAMP accumulation (calculated as pEC50 
value, here defined as the negative logarithm of the EC50 value).
Quantitative RT-PCR Analysis
Total RNA was isolated from zebrafish embryos using Trizol 
reagent (Invitrogen). Approximately 2 μg of total RNA were 
 retrotranscribed using M-MLV Reverse Transcriptase (Invitrogen). 
Quantitative real-time PCR (qRT-PCR) was performed with a 
Biorad iCycler iQ Real-Time PCR Detection System using iQ 
SYBR Green Supermix (Biorad, Hercules, CA) according to 
manufacturer’s instructions. Primers sequence were as follows: 
EphB4 (forward: 5ʹ-GGGGCCTGCAGGAGAGACCA-3ʹ, reverse: 
5ʹ-GATCCGCGCTCCTTCTCGCA-3ʹ); VE-cadherin (forward: 
5ʹ-TGACGAGGAGGGCGGAGGAG-3ʹ, reverse: 5ʹ-AGGTCCCACA 
CTGGGCCGAA-3ʹ); β-actin (forward: 5ʹ-CGAGCAGGAGATG 
GGAACC-3ʹ, reverse: 5ʹ-CAACGGAAACGCTCATTGC-3ʹ).
Samples were analyzed in triplicate, normalized against the thresh-
old cycle (Ct) of β-actin, and expressed as changes with respect to the 
levels of the gene under investigation in control samples.
HUVEC Cultures
HUVECs were grown in M199 medium (Invitrogen) supplemented 
with 20% fetal calf serum (Invitrogen), endothelial cell growth fac-
tor (100 μg/mL, Sigma), and porcine heparin (100 μg/mL, Sigma). 
HUVECs were used at early passages (I–V) and grown on plastic sur-
face coated with porcine gelatin (Sigma). When indicated, HUVECs 
were transfected with control-scrambled siRNA or with specific 
S1P1 siRNAs (TAGCATTGTCAAGCTCCTAAA, S1P1 siRNAa; and 
CTCGGTCTCTGACTACGTCAA, S1P1 siRNAb; both from Qiagen, 
Chatsworth, CA) using the HiPerFect Transfection Reagent (Qiagen) 
according to the manufacturer’s instructions. Transfection efficiency 
was equal to 70% to 80% as shown by transfection with a fluorescein-
conjugated control siRNA.
Western Blot Analysis of HUVECs
HUVECs were incubated with 30-μmol/L W146 for 48 hours, and 
cells lysates were probed with anti-EPHB4 antibody in a Western 
blot (Santa Cruz Biotechnology). Uniform loading of the gels was 
assessed using anti-focal adhesion kinase antibodies. In the second 
set of experiments, S1P1 siRNA-transfected HUVECs were analyzed 
96 hours after transfection by Western blotting with anti-EPHB4 and 
anti-S1P1 antibodies (Santa Cruz Biotechnology). The corresponding 
immunoreactive bands were quantified by computerized image analy-
sis and data were normalized for the intensity of the control tubulin 
band in the same sample.
Immunofluorescence Analysis of HUVECs
Cells were seeded on gelatine-coated coverslips in complete cell 
culture medium and allowed to reach confluence. Then, confluent 
cells were incubated for 24 hours in the absence or in the presence 
of TNYL-RAW or SCR-WTL (both at 100 μmol/L), washed, fixed in 
4% paraformaldehyde in PBS, permeabilized with 0.2% Triton-X100, 
and blocked with 10% BSA/0.1% Triton-X100 in PBS. Then, cells 
were incubated with the mouse anti-ZO1 antibody followed by incu-
bation with Alexa Fluor 488 anti-mouse IgG (Invitrogen) and nuclear 
counterstained with 4ʹ,6-diamidino-2-phenylindole (DAPI). Then, 
cells were photographed using a LSM510 Meta confocal microscope 
equipped with a Plan-Apochromat ×63/1.4 NA oil objective.
Results
Vascular Expression of zS1P1
The complete coding sequence of zS1P1 (GenBank accession 
no. NM_131691) was cloned from the total RNA isolated from 
zebrafish embryos at 24 hpf. In keeping with previous obser-
vations,13 zS1P1 encodes for a putative 362 amino acid protein 
highly homologous to human and murine S1P1 receptors (70% 
and 71% similarity, respectively). Accordingly, both the selec-
tive S1P1 receptor agonists SEW287126 and CYM544217 and 
the nonselective S1P receptor agonists S1P, dhS1P, and syn-
thetic FTY720-P27 potently inhibit forskolin-induced cAMP 
accumulation in Chinese hamster ovary–FlpIn cells transiently 
transfected with the zS1P1 cDNA with the following rank-
ing order: FTY720-P>dhS1P≈S1P>CYM5442≈SEW2871 
(Table). Similar results were obtained for Chinese hamster 
ovary–FlpIn cells transiently transfected with the human S1P1 
cDNA (Table), thus, confirming that zS1P1 encodes for the 
bona fide zebrafish ortholog of the human S1P1 gene.
On this basis, we analyzed the expression pattern of the 
zS1P1 gene in zebrafish embryos by whole-mount ISH. In 
agreement with previous observations,13 zS1P1 expression is 
restricted to the diencephalon at early somitogenesis (data 
not shown) and is widespread in the brain and neural tube at 
subsequent stages of development (Figure 1). Interestingly, 
whole-mount ISH showed also a transient but significant 
expression of zS1P1 transcript in the axial vasculature of the 
trunk of zebrafish embryos. This vascular pattern expression 
occurs at 24 hpf (Figure 1A and 1B), is maintained at 26 hpf 
(Figure 1D and 1E), and decreases at 30 hpf (Figure 1G and 
1H), being lost at 48 hpf (data not shown). Analysis of the 
cross sections of the trunk of 24, 26, and 30 hpf embryos con-
firmed that, in addition to the neural tube, zS1P1 marks the 
Table. Pharmacological Characterization of zS1P1 Receptor
Receptor Agonist* zS1P1(pEC50)
† hS1P1(pEC50)
†
S1P 9.0±0.3 9.1±0.2
dhS1P 9.2±0.1 9.7±0.1
FTY720-P 10.5±0.1 10.8±0.4
SEW2871 7.5±0.2 7.9±0.1
CYM-5442 7.7±0.1 8.3±0.1
zS1P1 indicates zebrafish ortholog of the endothelial sphingosine-1-
phosphate receptor-1; dhS1P, dihydro-S1P.
*Chinese hamster ovary–FlpIn cells were transiently transfected with 
zebrafish zS1P1 or human hS1P1 receptor cDNAs and treated with the indicated 
receptor agonists.
†Data are expressed as the potency of the indicated compound to inhibit 
forskolin-induced cAMP accumulation (calculated as pEC50 value, here defined 
as the negative logarithm of the EC50 value) and represent the mean±SEM of 
2 to 3 independent experiments. No effect was observed in mock-transfected 
cells (data not shown).
Tobia et al  S1P1 and Zebrafish Vascular Barrier Integrity  e107
endothelium of the main medial dorsal aorta (DA) and pos-
terior cardinal vein (PCV), as well as the basal aspect of the 
somites (Figure 1C, 1F, and 1I).
Endothelial differentiation in zebrafish is under the control 
of the sonic hedgehog/vascular endothelial growth factor 
(shh/vegf) genetic pathway.28 Endothelial expression of zS1P1 
in the axial vasculature of the trunk of 26 hpf embryos was 
abrogated by treatment with cyclopamine, a potent inhibitor 
of shh signaling29 (data not shown) or after downregulation 
of vegf expression by antisense MO injection (Figure 2). 
Specificity of the effect was demonstrated by the lack of effect 
of both treatments on somitic and central nervous system 
expression of zS1P1, thus, indicating that endothelial zS1P1 
expression is under the control of the shh/vegf cascade.30
MO Knockdown of zS1P1 Function Results 
in Venous Vascular Barrier Defects
To assess the functional role of zS1P1 in zebrafish vascu-
lar development, we used an antisense MO knockdown 
approach.31 To this purpose, a MO was designed directed 
against the 5ʹ untranslated region spanning the zS1P1 ATG 
start codon to inhibit protein translation (zS1P1-MO). Next, 
tg(fli1:EGFP)y1 transgenic zebrafish embryos in which EGFP 
expression is driven by the promoter of the pan-endothelial 
marker fli-1 were injected at the 1- to 4-cell stage with dif-
ferent doses of zS1P1-MO (ranging from 0.1–0.4 pmoles/
embryo) or of control std-MO and the development of EGFP–
labeled blood vessels was directly observed in live embryos.
Figure 1. Vascular expression of the zebrafish ortholog of the endothelial sphingosine-1-phosphate receptor-1 (zS1P1). A, D, and G, 
zS1P1 expression was analyzed in zebrafish embryos by in situ hybridization at the indicated developmental stages. Embryos are anterior 
to the left and lateral to the top. B, E, and H, High magnification of the area in black boxes in A, D and G. C, F, and I, Transverse sec-
tions through the trunk highlighted as vertical black bars in A, D, and G. zS1P1 is expressed by the axial vasculature of the trunk (white 
arrow indicates dorsal aorta [DA]; yellow arrow, posterior cardinal vein [PCV)). Transverse sections confirm zS1P1 expression in DA and 
PCV (black arrowheads), in the basal aspect of the somites (black arrows), and in neural tube (nt). nc indicates notocord; hpf, hours 
postfertilization.
Figure 2. Vascular zebrafish ortholog of 
the endothelial sphingosine-1-phosphate 
receptor-1 (zS1P1) expression is mediated 
by vascular endothelial growth factor (vegf). 
zS1P1 expression was assessed by in situ 
hybridization in standard-MO (std-MO) (A) 
and vegf-MO–injected embryos (B) at 28 
hpf. Note the absence of zS1P1 transcript 
in dorsal aorta (DA) and posterior cardinal 
vein (PCV) of vegf morphants. White arrow 
indicates dorsal aorta; yellow arrow, PCV.
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Whole–mount microscopic analysis of 24-hpf embryos 
injected with 0.4 pmoles/embryo of zS1P1-MO revealed the 
presence of pericardial edema and enlargement of the PCV 
(Figure 3C and 3D) whose altered structure was confirmed by 
the analysis of histological semithin cross sections of the trunk 
of zS1P1 morphants (Figure 4). At 2.5 days postfertilization 
(dpf), intersomitic vessels of all zS1P1-MO–injected embryos 
(n=181) appear slightly thinner than in control Std-MO–
injected embryos (Figure 3J). Also, zS1P1 downregulation was 
associated with minor defects in the development of the duct 
of Cuvier and of the subintestinal vein basket in all mophants 
(Figure 3K and 3L). In keeping with the modest impact of 
zS1P1 downregulation on blood vessel development, no 
differences in the expression of shh, vegf, kdr, and fli-1 genes 
were observed in zS1P1-MO–injected versus Std-MO–injected 
embryos (data not shown). These data support previous 
observations in S1P1-null mice indicating that this S1P 
receptor is not essential for vasculogenic and angiogenic events 
Figure 3. Vascular defects in the zebrafish ortholog of the endothelial sphingosine-1-phosphate receptor-1 (zS1P1) morphants. Vascu-
lar morphology in tg(fli1:EGFP)y1 embryos injected with standard-MO (std-MO) or zS1P1-MO. Morphological appearance of control (A) 
and zS1P1 morphant (C) embryos at 24 hours postfertilization (hpf). The pericardial edema in zS1P1 morphants is indicated by a black 
arrow in C. Trunk regions highlighted by black boxes are shown at higher magnification in B and D where dorsal aorta (DA) and posterior 
cardinal vein (PCV) are indicated by white and yellow bars, respectively; note the abnormal size of PCV in zS1P1 morphants (D). E and 
F, Epifluorescence microscopy of std-MO– and zS1P1-MO–injected tg(fli1:EGFP)
y1 embryos at 2.5 days postfertilization (dpf). Trunk and 
Duct of Cuvier regions highlighted by yellow and red boxes, respectively, are shown at higher magnification in (G), (H), (J), and (K); white 
arrowheads point to thinner intersomitic vessels (J) and to poorly developed Duct of Cuvier (K) in zS1P1 morphants. I and L, Alkaline 
phosphatase staining of 3-dpf embryos revealed alterations of subintestinal vessel organization in zS1P1 morphants (L). M and N, zS1P1 
knockdown causes absence of blood circulation as shown by microangiography performed at 50 hpf. O and P, Morphological appear-
ance of control and zS1P1 morphant larvae at 6 dpf; note the generalized edema in zS1P1 morphants (P). Q, Dose-dependent effects of 
zS1P1 knockdown: white bars, pericardial edema; black bars, absence of blood circulation; gray bars, late generalized edema (each point 
is the mean±SD of 97–181 embryos per group).
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during embryogenesis.5 However, despite minor alterations in 
vascular development, the presence of a beating heart with no 
major developmental defects (Figure 5) and of a patent lumen 
in both DA and PCV cross sections (Figure 4), zS1P1-MO–
injected embryos showed no apparent blood circulation, 
as confirmed by the absence of tetramethylrhodamine 
isothiocyanate–dextran perfusible vessels at 50 hpf (Figure 
3N). Of note, 6 dpf zS1P1-MO–injected embryos showed a 
remarkable generalized edema never observed in control 
embryos (Figure 3P). The incidence of phenotypic alterations 
(early pericardial edema, lack of blood circulation, and late 
generalized edema) was directly related to the dose of injected 
zS1P1-MO, 100% of the embryos showing all these defects 
when injected with 0.4 pmoles/embryo (Figure 3Q). The 
appearance of the generalized edema, already evident at 4 dpf, 
was fully prevented when zS1P1 morphants were grown in 
fish water containing 250 mmol/L D-mannitol. Nevertheless, 
blood circulation was not restored (data not shown).
To confirm the specificity of the vascular and circulatory 
defects in zS1P1 morphants, zS1P1-MO was coinjected with a 
MO-resistant form of the human S1P1 mRNA. In 2 indepen-
dent experiments, analysis of the embryos at 30 hpf showed 
the ability of the human transcript to rescue the zS1P1-knock-
down phenotype, as assessed by the presence of normal blood 
flow in 76% of rescued embryos when compared with 36% 
of zS1P1 morphants (P<0.001; Fisher exact test; Figure 6A). 
Also, analysis of the embryos at 6 dpf showed the ability of 
the human transcript to rescue the generalized edema observed 
in zS1P1 morphants. In fact, only 34% of zS1P1 morphants 
coinjected with the human S1P1 mRNA developed general-
ized edema when compared with 57% of zS1P1 morphants 
(P<0.001; Fisher exact test; Figure 6B).
S1P1 receptor and its ligand S1P play an important role 
in the control of vascular barrier by affecting endothelial 
cell–cell junctions,15 including the expression of the adhe-
rens junction component VE-cadherin.10 The phenotype 
observed in zS1P1 morphants prompted us to assess the pos-
sibility that zS1P1 may control endothelial barrier integrity 
in zebrafish. On this basis, the effect of zS1P1 downregula-
tion on the organization of endothelial cell–cell junctions 
was investigated by whole-mount ISH of VE-cadherin32 
expression in the axial vasculature of the trunk and by 
immunofluorescence analysis of ZO1, a tight junction– 
associated protein functionally critical in regulating S1P-
mediated endothelial barrier integrity.33 As shown in Figure 
7B, zS1P1 knockdown caused the selective downregulation 
of VE-cadherin in the PCV but not in the DA of zS1P1 mor-
phants. In keeping with the ISH data, the RT-PCR analysis 
showed a decrease of steady state VE-cadherin mRNA levels 
in zS1P1 morphants when compared with control embryos 
(31%±12%, average of the 2 independent experiments). 
Figure 4. Alterations of posterior cardinal vein (PCV) morphol-
ogy in the zebrafish ortholog of the endothelial sphingosine-
1-phosphate receptor-1 (zS1P1) morphants. Histological semithin 
cross sections of the trunk of 28 hours postfertilization embryos 
demonstrate the altered structure of the PCV in S1P1 morphants 
when compared with standard-MO (std-MO)–injected embryos. 
White arrows indicate dorsal aorta; yellow arrows, PCV.
Figure 5. Effect of the zebrafish ortholog of the endothelial 
sphingosine-1-phosphate receptor-1 (zS1P1) knockdown on car-
diac myogenesis gene expression. Standard-MO (std-MO)– and 
zS1P1-MO–injected embryos (n=14) were grown in fish water 
containing 250 mmol/L D-mannitol and analyzed at 28 hours post 
fertilization (hpf) for the expression of the cardiac myogenesis 
gene markers ventricular myosin heavy chain (vmhc; A and B), 
atrial myosin heavy chain (amhc; C and D), and cardiac myosin 
light chain 2 (cmlc2; E and F). No alterations were observed in 
zS1P1 morphants when compared with controls. At later stages 
of development (48 hpf), minor defects in cmlc2 expression were 
observed only in a limited number of zS1P1 morphants (11/33) 
(data not shown).
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Also, confocal microscopy analysis of the vasculature of 
the trunk of control and zS1P1 morphants at 30 hpf revealed 
a complete disorganization of the ZO1+ endothelial junc-
tions in the PCV of all the zS1P1 morphants examined (n=5) 
(Figure 7D). Instead, no effect on ZO1 immunolocalization 
was observed in the DA of zS1P1 morphants (Figure 7D) 
and in both axial vessels of std-MO–injected embryos 
(Figure 7C). Together, the data indicate a nonredundant 
Figure 6. Human hS1P1 overexpression 
rescues vascular defects in the zebrafish 
ortholog of the endothelial sphingosine-
1-phosphate receptor-1 (zS1P1) morphants. 
zS1P1 morphants were injected with hS1P1 
mRNA and lack of blood flow (A) and 
generalized edema (B) were analyzed at 
30 hours postfertilization and 6 days post-
fertilization (dpf), respectively. hS1P1 over-
expression caused a significant increase 
in the percentage of embryos with normal 
blood flow (122/161 [76%) vs 42/117 
[36%] zS1P1 morphants injected or not 
with hS1P1 mRNA, respectively; P<0.001, 
Fisher exact test) and in the percentage of 
embryos devoid of a significant general-
ized edema (100/152 [66%] vs 48/112 
[43%] zS1P1 morphants injected or not 
with hS1P1 mRNA, respectively; P < 0.001, 
Fisher exact test). Western blot analysis 
confirmed the increased expression of 
S1P1 protein in 24 hpf zebrafish embryos 
injected with hS1P1 mRNA when com-
pared with noninjected animals (inset in A; 
human umbilical vascular endothelial cells 
[HUVEC] extract was used as a control and 
uniform loading of the gel was assessed 
with anti–α-tubulin [α-tub] antibodies). C, 
The loss of EphB4a and vascular endo-
thelial cadherin (VE-cadherin) expression 
in posterior cardinal vein (PCV) of zS1P1 
morphants (43/60 [72%] and 33/44 [75%) 
embryos in two different experiments) was 
reduced to 4/17 (24%) and 9/36 (25%) 
embryos coinjected with the human S1P1 
mRNA (P<0.001, Fisher exact test). White 
arrow indicates DA; yellow arrow, PCV.
Figure 7. The zebrafish ortholog of the 
endothelial sphingosine-1-phosphate 
receptor-1 (zS1P1) knockdown affects Vas-
cular endothelial cadherin (VE-cadherin) 
expression and zonula occludens 1 (ZO1) 
immunolocalization in posterior cardinal 
vein (PCV). Standard-MO (std-MO)– and 
zS1P1-MO–injected embryos were ana-
lyzed at 28 hpf for the expression of VE-
cadherin by in situ hybridization (A and B) 
and immunostained for ZO1 at 30 hours 
postfertilization (C and D). Dorsal aorta (DA) 
and PCV are indicated by white and yellow 
symbols, respectively. zS1P1 morphants 
were characterized by the downregulation 
of VE-cadherin expression (33/44 embryos 
examined) and altered ZO1 organization in 
PCV (asterisk in D) but not in DA (D) (5/5 
embryos examined). In contrast, normally 
organized ZO1+ junctions were observed in 
both axial vessels of control embryos (C). 
Transverse sections highlighted as verti-
cal green dotted bars confirm VE-cadherin 
downregulation in PCV of zS1P1 morphants 
when compared with controls (insets in A 
and B).
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vascular function for zS1P1 that affects venous endothelial 
cell–cell barrier in zebrafish.
Downregulation of Venous Endothelial 
EphB4a Expression in zS1P1 Morphants
The selective effect of zS1P1 knockdown on PCV structure, 
VE-cadherin expression, and ZO1 organization prompted us 
to investigate the expression of arterial and venous markers in 
the axial vessels of the trunk in zS1P1-MO–injected embryos. 
As shown in Figure 8, zS1P1 downregulation does not affect 
the expression of the specific arterial markers ephrinB230 
and crlr34 in the DA of zS1P1 morphants. Also, zS1P1-MO 
injection does not alter the expression of the venous markers 
flt435 and dab236 in the PCV. Thus, in keeping with previous 
observations in S1P1 null mice,5 the data indicate that zS1P1 
knockdown does not affect arterial/venous differentiation of 
endothelial cells in zebrafish. However, zS1P1 downregulation 
caused the loss of the expression of the Eph receptor EphB4a 
in the PCV of zS1P1-MO–injected embryos (Figure 8J), as 
confirmed by the decrease of steady state EphB4a mRNA 
levels in zS1P1-null embryos when compared with controls 
(38%±9%, average of the 2 independent quantitative RT-PCR 
experiments). Of note, zS1P1 downregulation did not affect 
the expression of EphB4a in the gut of zebrafish embryos, 
thus demonstrating the specificity of the effect of zS1P1-MO 
on EphB4a expression in PCV (asterisk in Figure 8I and 8J).
The loss of EphB4a and VE-cadherin expression in venous 
endothelium of zS1P1 morphants (72% and 75% of zS1P1 mor-
phants, respectively) was significantly reduced to 24% and 
25% for the 2 genes in embryos coinjected with the human 
S1P1 mRNA (Figure 6C), thus confirming the specificity of the 
effect (P<0.001, Fisher exact test). Also, heart beating arrest 
after treatment with a high dose of ethyl-m- aminobenzoate 
(tricaine) did not affect EphB4a and VE-cadherin expres-
sion in zebrafish embryos (n=22), thus, indicating that the 
observed downregulation of these genes in zS1P1 morphants 
is not the direct consequence of the lack of blood flow (Figure 
9). Finally, coinjection of the human S1P1 mRNA fully res-
cued ZO1 organization in the PCV of zS1P1 morphants (data 
not shown). These observations point to a role for S1P1 recep-
tor in the control of venous endothelial cell functions and gene 
expression in zebrafish.
VE-cadherin Acts Upstream of EphB4a in 
Modulating Venous Vascular Barrier Organization
Previous observations had demonstrated a tight relationship 
between the expression of the members of the cadherin family 
of adhesion molecules and Eph receptors in epithelial cells.37 
On this basis, we addressed the possibility that the venous 
endothelial barrier defects in zebrafish embryos lacking zS1P1 
activity might be the consequence of defects in a putative 
zS1P1/VE-cadherin/EphB4a pathway.
To assess this hypothesis, we investigated the effect of 
VE-cadherin downregulation on EphB4a expression and 
vascular integrity in zebrafish morphants.32 As shown in 
Figure 10, embryos injected with VE-cadherin–MO 
(1.0 pmoles/embryo) showed downregulation of EphB4a 
expression (24/24 embryos), pericardial edema and lack 
of blood circulation (28/30 embryos, data not shown), and 
late generalized edema (19/22 embryos) with no changes 
in vascular zS1P1 expression (13/13 embryos). Also, 
VE-cadherin morphants revealed a complete disorganization 
of the ZO1+ endothelial junctions in PCV and DA of all the 
embryos examined (Figure 10H). These data extend previous 
observations about the role of VE-cadherin on vascular stability 
in zebrafish.32,38 On this basis, to assess whether exogenous 
VE-cadherin is sufficient to rescue EphB4a expression and 
vascular integrity in the absence of zS1P1 activity, zS1P1 
Figure 8. The zebrafish ortholog of the endothelial sphingosine-
1-phosphate receptor-1 (zS1P1) knockdown causes EphB4a 
downregulation in posterior cardinal vein (PCV). Standard-MO 
(std-MO)– and zS1P1-MO–injected embryos were analyzed at 28 
hours postfertilization for the expression of the indicated mark-
ers by in situ hybridization (lateral view of the trunk region; dorsal 
aorta (DA), white arrow; PCV, yellow arrow). zS1P1 morphants 
were characterized by the lack of expression of EphB4a in the 
PCV (J; 43/60 embryos examined). In contrast, arterial markers 
ephrinB2 (B) and crlr (D) and venous markers flt4 (F) and dab2 
(H) were expressed in 9/10, 9/12, 11/12, and 14/18 zS1P1 mor-
phants, respectively. All genes were instead normally expressed 
in all control embryos examined (A, C, E, G, and I; n=15–30). 
Note that EphB4a expression, downregulated in the PCV, is 
maintained in the gut of all the zS1P1 morphants (asterisk in I and 
J). Transverse sections highlighted as vertical black bars confirm 
EphB4a downregulation in the PCV of zS1P1 morphants when 
compared with controls (insets in I and J).
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morphants were injected with the mRNA encoding for murine 
VE-cadherin.32 As shown in Figure 11B and 11C, the loss of 
EphB4a expression in venous endothelium of zS1P1 morphants 
was significantly reduced in embryos coinjected with the 
murine VE-cadherin mRNA (78% versus 41% of morphants, 
respectively; P<0.001, Fisher exact test). Also, injection 
of VE-cadherin mRNA caused a significant decrease in the 
number of zS1P1 morphants showing early pericardial edema, 
lack of blood circulation, and late generalized edema (Figure 
11A). Accordingly, VE-cadherin mRNA overexpression 
rescued the organization of ZO1+ endothelial junctions in 
the PCV of zS1P1 morphants (Figure 11E). At variance, no 
rescue was observed after injection of zS1P1 morphants with 
VEGF-A mRNA, thus confirming the specificity of the effect 
(data not shown). These results suggest that the loss of EphB4a 
expression in zS1P1 morphants is a result of the VE-cadherin 
downregulation in PCV endothelium downstream of zS1P1, 
pointing to the existence of a zS1P1/VE-cadherin/EphB4a 
pathway modulating venous vascular barrier organization in 
zebrafish embryo.
EPHB4 Controls Barrier Integrity in HUVECs
The segregation of distinct arterial and venous vessels is dis-
rupted by EphB4a knockdown in zebrafish,39 hampering the 
possibility to use EphB4a morphants to directly assess the 
role of this receptor in PCV integrity. Also, EphB4a over-
expression severely affects the general development of S1P1 
morphants (data not shown), forbidding phenotypic rescue 
experiments in these embryos.
To overcome these limitations and to confirm that a S1P/
Eph receptor cross talk may modulate intercellular contacts 
also in mammalian venous endothelium, we took advantage 
of HUVECs that express both S1P140 and the Eph receptor 
EPHB4.19 As anticipated, a 1-hour pretreatment of confluent 
HUVECs with 30 μmol/L of the selective S1P1 antagonist 
W14615 prevents ZO1+ intercellular junction assembly trig-
gered by a 2-hour treatment with 62.5 nmol/L S1P (data not 
shown) and causes a potent inhibition of EPHB4 expres-
sion in both control and S1P-treated HUVECs as assessed 
by quantitative RT-PCR (87%±2% and 95%±1% inhibition, 
respectively; n=2). Accordingly, W146 treatment induces a 
significant inhibition of the levels of EPHB4 receptor protein 
in these cells (Figure 12A).
Only a limited inhibition of EPHB4 protein levels was 
observed after transfection with either 1 of the 2 different 
S1P1 siRNAs, each causing a partial downregulation of 
S1P1 expression (Figure 12B). However, the simultaneous 
Figure 9. EphB4a and vascular endothelial cadherin (VE-
cadherin) downregulation in zS1P1 morphants is not a result of 
the absence of blood circulation. In situ hybridization at 28 hour 
postfertilization revealing EphB4a and VE-cadherin expression 
in the posterior cardinal vein (PCV) of tricaine-treated embryos 
(C and D) and absent in the zebrafish ortholog of the endothe-
lial sphingosine-1-phosphate receptor-1 (zS1P1)-MO–injected 
embryos (A and B). White arrow indicates DA; yellow arrow, 
PCV. 
Figure 10. Vascular endothelial cadherin (VE-cadherin)–MO 
injection phenocopies the zebrafish ortholog of the endothe-
lial sphingosine-1-phosphate receptor-1 (zS1P1) knockdown. 
Standard-MO (std-MO)– and VE-cadherin-MO–injected embryos 
were analyzed for the appearance of generalized edema at 6 dpf 
(A and B), EphB4a and zS1P1 expression by in situ hybridiza-
tion at 28 hours postfertilization (hpf) (C–F) and immunostained 
with anti-ZO1 antibody at 30 hpf (G and H). Dorsal aorta (DA) 
and posterior cardial vein (PCV) are indicated by white and 
yellow symbols, respectively. VE-cadherin morphants were 
characterized by presence of generalized edema (B, 19/22 
embryos), downregulation of EphB4a (D, 24/24 embryos), and 
altered zonula occludens 1 (ZO1) organization in PCV and DA 
(asterisks in H). In contrast, normally organized ZO1+ junctions 
were observed in both axial vessels of control embryos (G). VE-
cadherin downregulation does not affect zS1P1 expression in DA 
and PCV (E and F).
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transfection with both S1P1 siRNAs allowed a more significant 
downregulation of S1P1 receptor and resulted in a remarkable 
decrease of EPHB4 protein levels (Figure 12B), with ≈25% to 
30% of the receptor levels detected in cells transfected with 
the scrambled siRNA as assessed by computerized image 
analysis of the immunoreactive bands (Figure 12C). Thus, 
in agreement with the data obtained with zS1P1 morphants, 
these results indicate that the suppression of S1P1 receptor 
expression (by siRNA transfection) or activity (by W146 
treatment) induces a significant downregulation of EPHB4 in 
HUVEC.
On this basis, we investigated the effect of the selective 
EPHB4 receptor antagonist TNYL-RAW peptide and of the 
control-scrambled peptide SCR-WTL18,19 on ZO1+ intercellu-
lar contact organization in HUVECs. Similar to W146 (data 
not shown), TNYL-RAW inhibited ZO1 organization in cell–
cell junctions of confluent HUVEC monolayers maintained 
in serum-containing cell culture medium, whereas no effect 
was exerted by the control-scrambled peptide SCR-WTL 
(Figure 12D). In keeping with our observations in zebrafish 
embryos, these data support a direct functional role for the 
Eph receptor EPHB4 in mediating S1P1-dependent organiza-
tion of ZO1+ intercellular junctions in venous endothelium.
Discussion
In this study, we report the characterization and functional 
analysis of S1P1, a major endothelial S1P receptor, in the 
development of vascular system in zebrafish embryo. Here 
we show that S1P1 plays a nonredundant role in the regula-
tion of endothelial barrier in zebrafish via a novel S1P1/VE-
cadherin/EphB4a genetic pathway that controls venous 
vascular integrity.
In agreement with previous observations,13 pharmacologi-
cal characterization based on the effect of nonselective and 
selective S1P1 receptor agonists on forskolin-induced cAMP 
accumulation demonstrates that the binding properties of the 
cloned zS1P1 receptor expressed in mammalian cells are simi-
lar to those shown by its human counterpart, thus confirm-
ing that zS1P1 encodes for the bona fide zebrafish ortholog 
of the human S1P1 gene. Consistent with a vascular pattern 
of expression of S1P1 in mouse embryo,5 zS1P1 is expressed 
in the axial vasculature of the trunk of zebrafish embryos, 
whole-mount ISH showing that zS1P1 transiently marks the 
endothelium of DA and PCV at 24 to 30 hpf, being lost at 
48 hpf. The shh signaling inhibitor cyclopamine or vegf anti-
sense MO both abrogate expression of zS1P1 in the axial vas-
culature of the trunk, thus indicating that endothelial zS1P1 
expression is under the control of the endothelial differen-
tiation shh/vegf genetic pathway.30 These data extend previ-
ous observations about the ability of vascular endothelial 
growth factor to upregulate S1P1 expression in mammalian 
endothelium.41
Here, we show that zS1P1 morphants are characterized by 
minor defects in the vascular development of intersomitic 
vessels, duct of Cuvier, and subintestinal vein basket. This 
was paralleled by early pericardial edema, lack of blood 
circulation, alterations of PCV structure, and a dramatic late 
generalized edema. Interestingly, several of these phenotypic 
features were observed also in S1P1 null mice,5 as well as in 
VE-cadherin zebrafish morphants  (C. Tobia, our unpublished 
observations, 2010).32 However, S1P1-null mice exhibit 
massive embryonic hemorrhage and deficient smooth muscle 
cell/pericyte recruitment in embryonic vasculature,5 defects 
that were not observed in zS1P1 morphants. These species 
differences may be, at least in part, a result of the fact that 
zebrafish is characterized by a delay in smooth muscle cell/
pericyte maturation with a very limited PCV coverage with 
respect to mammals.42 Indeed, transgelin-positive mural cells 
are not yet detectable in PCV of zebrafish embryos at 80 hpf 
Figure 11. Murine vascular endothelial cadherin (VE-cadherin) 
overexpression rescues vascular defects in the zebrafish ortholog 
of the endothelial sphingosine-1-phosphate receptor-1 (zS1P1) 
morphants. A, zS1P1 morphants were left untreated (n=72) or 
were injected with murine VE-cadherin mRNA (n=123), and their 
phenotype was analyzed for the presence of pericardial edema 
and lack of blood flow at 48 hours post fertilization (hpf) and 
late generalized edema at 5 dpf. mVE-cadherin overexpression 
rescued all these vascular alterations in zS1P1 morphants. B–E, 
Control and mVE-cadherin mRNA-–injected zS1P1 morphants 
were analyzed at 28 hpf for the expression of EphB4a (B and C) 
and immunostained for zonula occludens 1 (ZO1) at 30 hpf (D 
and E). Dorsal aorta (DA) and posterior cardinal vein (PCV) are 
indicated by white and yellow symbols, respectively. The loss 
of EphB4a in PCV of zS1P1 morphants (60/77 [78%] embryos in 
3 different experiments) was reduced to 31/76 (41%) embryos 
coinjected with mVE-cadherin mRNA (C; P<0.001, Fisher exact 
test). Also, normal ZO1 immunolocalization was observed in the 
PCV of all the observed mVE-cadherin mRNA–injected zS1P1 
morphants (E).
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or 120 hpf,42 when the vascular defects in zS1P1 morphants are 
already established.
Lack of blood circulation and pericardial edema have been 
observed also in S1P2 receptor mil zebrafish mutants as a 
consequence of profound defects in heart organogenesis.14 At 
variance with mil mutants, we did not observe major defects 
in the developing heart of the zS1P1 morphants, as indicated 
by the normal pattern of expression of the cardiac myogenesis 
genes ventricular myosin heavy chain, atrial myosin heavy 
chain, and cardiac myosin light chain 2 (see Figure 5), 
demonstrating that the 2 S1P receptors play different roles in 
zebrafish development.
Edema formation may result from cardiovascular, lym-
phatic vascular or excretory system defects. To this respect, 
zS1P1 morphants showed an apparently normal lymphatic 
thoracic duct at 4 dpf (C. Tobia, unpublished observations, 
2010). Also, high molecular weight proteins (≥80 000) were 
present in the extravascular transudate we collected from 
edematous zS1P1 morphants at 6 dpf but not in the transudate 
collected from prox-1 morphants showing lack of lymphatic 
vessel development43 as observed by SDS-PAGE (C. Tobia, 
unpublished observations, 2010). Thus, even though the 
effect of zS1P1 knowdown on cardiac, lymphatic and excre-
tory system development and function will deserve further 
investigation, our observations suggest that alterations of 
endothelial barrier integrity may contribute, at least in part, 
to the edematous phenotype observed in zS1P1 morphants. 
Actually, in keeping with a role for S1P1 in vascular bar-
rier integrity, zS1P1 morphants showed significant altera-
tions of vessel morphology, downregulation of VE-cadherin 
expression, and ZO1 disorganization in PCV but not in DA. 
It must be pointed out that zS1P1 knockdown did not affect 
arterial/venous differentiation of endothelial cells in zebraf-
ish. Indeed, zS1P1 morphants did not show any change in the 
levels of expression of shh, vegf, kdr, and fli-1, as well as of 
the arterial markers ephrinB230 and crlr34 and of the venous 
markers flt435 and dab2,36 thus confirming previous observa-
tions in S1P1−/− mice.5 Nevertheless, the expression of the Eph 
receptor EphB4a was significantly downregulated in zS1P1-
MO–injected embryos. To this respect, it is interesting to note 
that EphB4a knockdown after MO injection at 1- to 4-cell 
stage has a dramatic impact on early vascular development 
and arterial/venous segregation in zebrafish.39 In contrast, as 
stated above, EphB4a downregulation in zS1P1 morphants, 
which occurs at 28 hpf in the already differentiated PCV, is 
paralleled only by minor defects in late vascular develop-
ment, mostly affecting venous microcirculation (ie, the duct 
of Cuvier and the subintestinal vein basket) with no apparent 
effect on arterial/venous differentiation. Taken together, these 
data suggest that EphB4a may play a dual role in the circula-
tory system of zebrafish: an earlier effect on arterial/venous 
differentiation and a later effect on venous vascular integrity. 
In keeping with this hypothesis, EphB4a has been shown to 
regulate venous remodelling in the adult murine vasculature.44
Figure 12. EPHB4 controls barrier integrity in human umbilical vein endothelial cells (HUVECs). A, HUVECs were incubated with vehicle 
or with 30-µmol/L W146 for 48 hours and cells lysates were probed with anti-EPHB4 antibody in a Western blot. B, HUVECs were left 
untreated (n.t.), mock transfected, or transfected with control-scrambled short interfering RNA (siRNA), 2 different S1P1 siRNAs (a or b) or 
the pool of the 2 S1P1 siRNAs (a+b). After 96 hours, cell lysates were probed by Western blotting with anti-S1P1 and anti-EPHB4 antibod-
ies. Uniform loading of the gels was assessed with anti-focal adhesion kinase (FAK) (A) or anti-tubulin (B) antibodies. C, The cell lysates 
of untreated, mock transfected, scrambled siRNA–transfected, and endothelial sphingosine-1-phosphate receptor-1 (S1P1) siRNAs 
(a+b)–transfected HUVECs were probed by Western blotting with anti-S1P1 and anti-EPHB4 antibodies, and the corresponding immu-
noreactive bands were quantified by computerized image analysis and normalized for tubulin levels. The data are the mean±SD of the 3 
independent transfection experiments and are expressed as percentage of immunoreactive protein levels in untreated cells. D, Confluent 
HUVECs were treated with vehicle or with 100 µmol/L control SCR-WTL peptide or TNYL-RAW peptide for 24 hours in complete cell cul-
ture medium. Then, cells were immunostained with anti–zonula occludens 1 (ZO1) antibody. Note that ZO1 localization in cell–cell contact 
regions is lost in TNYL-RAW–treated cells.
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Eph receptors have been implicated in the permeability of 
epithelial and endothelial barriers45 and EphA receptors have 
been suggested to act downstream of E-cadherin to mediate 
epithelial cell-to-cell contacts.37 Our data strongly suggest 
that a cadherin/Eph receptor cross talk may exist also in the 
endothelial cells, genetic VE-cadherin/EphB4a interactions 
mediating venous vascular integrity downstream of S1P1. 
Several experimental evidences support this hypothesis. 
(1) The S1P/S1P1 receptor system modulates VE-cadherin 
expression and the localization of this adherens junction 
component at intercellular junctions in mammalian endo-
thelium.10 (2) zS1P1 knockdown causes VE-cadherin and 
EphB4a downregulation in PCV of zebrafish morphants. 
(3) Both zS1P1 morphants and VE-cadherin morphants 
show early pericardial edema, lack of blood circulation, 
late generalized edema, disorganization of endothelial ZO1+ 
junctions, and EphB4a downregulation. (4) Exogenous 
VE-cadherin is sufficient to rescue EphB4a expression and 
vascular integrity in the absence of zS1P1 activity. (5) Stable 
S1P1 knockdown downregulates VE-cadherin expression 
in different human endothelial cells lines.46 (6) In keeping 
with the data obtained in zS1P1 zebrafish morphants, S1P1 
siRNA transfection and the selective S1P1 antagonist W14615 
downregulate EPHB4 receptor expression in mammalian 
HUVECs. (7) Similar to W146, the selective EPHB4 recep-
tor antagonist TNYL-RAW peptide18,19 prevents ZO1+ inter-
cellular contact organization in the same cells. Together, the 
data point to the existence of a S1P1/VE-cadherin/EphB4a 
genetic pathway modulating vascular barrier organization in 
venous endothelium.
At present, the molecular mechanism(s) orchestrating this 
genetic pathway remain unravelled. To this respect, the capac-
ity of zS1P1 in modulating intercellular barrier appears to be 
restricted to venous endothelium. Indeed, even though zS1P1 
receptor is expressed in both DA and PCV endothelial cells, 
its knockdown results in VE-cadherin downregulation with 
consequent alterations of vessel morphology and disorgani-
zation of ZO1+ endothelial junctions only in PCV, with no 
apparent alterations of arterial endothelium. This indicates 
that VE-cadherin expression and endothelial barrier integrity 
are controlled by different mechanisms in venous and arterial 
endothelium of zebrafish embryo.
Endothelium demonstrates remarkable heterogeneity in 
structure and function.47 Within the microvasculature, junc-
tions are tighter in arterioles compared with capillaries and are 
quite loose in venules, likely reflecting the role of postcapil-
lary venules in mediating inflammation-induced extravasation 
of leukocytes and plasma constituents.48 Accordingly, differ-
ences in the expression of adherens junctional proteins have 
been reported in arterial versus venous endothelial cells.49,50 
Several transcription factors, including members of the E-26 
and Twist/Slug/Snail families, and Wnt/β-catenin signaling 
regulate VE-cadherin expression.51 Further experiments are 
required to elucidate the transcriptional and signaling mecha-
nisms responsible for the observed modulation of VE-cadherin 
expression in human46 and zebrafish (present work) endothe-
lium by S1P1 knockdown and the molecular bases responsible 
for the different responses of venous and arterial vascular beds 
to zS1P1 downregulation in zebrafish embryo.
Alterations of the endothelial barrier integrity may occur in 
different pathological conditions, including acute respiratory 
distress syndrome in the lung, ischemia-reperfusion stresses 
in the kidney and myocardium, and experimental autoimmune 
encephalomyelitis in the brain. In all these conditions, S1P 
receptor activation may favour vascular integrity, synthetic 
chemical agonists/antagonists of S1P receptors representing 
therapeutic modulators of the endothelial barrier.4 Zebrafish 
is suitable for high-throughput screening of chemical com-
pounds using robotic platforms.52,53 Also, zebrafish has been 
proposed as a suitable animal model of human vascular mal-
formation disorders.6 Our findings indicate that this animal 
model may provide useful information about the molecular 
mechanisms regulating vascular barrier integrity and may be 
used for the screening of novel endothelial barrier-targeting 
therapeutics.
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